Advances in Nano Drugs for Cancer Chemotherapy

被引:127
作者
Ali, I. [1 ]
Rahis-Uddin [1 ]
Salim, K. [1 ]
Rajora, A. K. [1 ]
Rather, M. A. [1 ]
Wani, W. A. [1 ]
Haque, A. [1 ]
机构
[1] Jamia Millia Islamia, Dept Chem, New Delhi 110025, India
关键词
Cancer; nano drugs; chemotherapy; mechanism of action; GLYCOL CHITOSAN NANOPARTICLES; ADVANCED COLORECTAL-CANCER; CELL LUNG-CANCER; EVERY; WEEKS; PHASE-I; BREAST-CANCER; LIPOSOMAL CISPLATIN; SOLID TUMORS; BIOMEDICAL APPLICATIONS; PACLITAXEL POLIGLUMEX;
D O I
10.2174/156800911794328493
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In spite of some medications, millions of people are dying every year due to cancer. Additionally, the survival patients suffer from various serious side effects due to the use of available anti-neoplastic medicines. The development of nanoparticle based drugs seems to be effective providing low side effects and targeted action on cancer cells. The present article describes the state-of-the-art of nano drugs in cancer chemotherapy. The nano drugs are target selective and specific towards tumors only resulting into better treatment. The important molecules used for preparation nano drugs are cisplatin, carboplatin, bleomycin, 5-fluorouracil, doxorubicin, dactinomycin, 6-mercaptopurine, paclitaxel, topotecan, vinblastin and etoposide etc. The most commonly used materials for nanoparticle carriers are dendrimers, polymers, liposomes, micelles, inorganic, organic nanoparticles etc. A survey was carried out on the drugs available in the market and given in tabular form. However, the commonly used nano drugs till date are liposome dendrimer and some other materials based on nanoparticles. Attempts have been made to explain the mechanism of action of nano drugs. The future perspectives have also been highlighted in the conclusion part.
引用
收藏
页码:135 / 146
页数:12
相关论文
共 131 条
[1]   Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes [J].
Agrawal, A ;
Tripp, RA ;
Anderson, LJ ;
Nie, SM .
JOURNAL OF VIROLOGY, 2005, 79 (13) :8625-8628
[2]   PIONEER: A phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2 [J].
Albain, Kathy S. ;
Belani, Chandra P. ;
Bonomi, Philip ;
O'Byrne, Kenneth J. ;
Schiller, Joan H. ;
Socinski, Mark .
CLINICAL LUNG CANCER, 2006, 7 (06) :417-419
[3]  
Alexiou C, 2000, CANCER RES, V60, P6641
[4]   New frontiers in nanotechnology for cancer treatment [J].
Alexis, Frank ;
Rhee, June-Wha ;
Richie, Jerome P. ;
Radovic-Moreno, Aleksandar F. ;
Langer, Robert ;
Farokhzad, Omid C. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2008, 26 (01) :74-85
[5]  
Allen Theresa M., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P513, DOI 10.2174/187152006778699121
[6]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[7]   LARGE UNILAMELLAR LIPOSOMES WITH LOW UPTAKE INTO THE RETICULOENDOTHELIAL SYSTEM [J].
ALLEN, TM ;
CHONN, A .
FEBS LETTERS, 1987, 223 (01) :42-46
[8]  
[Anonymous], 2006, CANC CONTROL KNOWLED
[9]  
Arayne M. S., 2006, PAK J PHARM SCI, V9, P256
[10]  
Bawa Raj, 2009, Nanomedicine, V5, P5